stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) Current ratio
NewAmsterdam Pharma Company N.V.'s current ratio at the end of the quarter to 30 September 2026 was 11.8×, up 3.9× from fiscal 2025 (7.9×). Over the past ten years it has ranged from 6.0× (fiscal 2021) to 13.3× (fiscal 2022); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 7.9× | (2.46%) |
| FY2024 | 8.1× | 16.19% |
| FY2023 | 7.0× | (47.57%) |
| FY2022 | 13.3× | 4.90% |
| FY2022 | 12.6× | 88.62% |
| FY2021 | 6.7× | 12.43% |
| FY2021 | 6.0× | (24.59%) |
| FY2020 | 7.9× | 0.00% |
| FY2020 | 7.9× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 11.8× | 30.19% |
| Jun 2026 | 9.0× | (7.45%) |
| Mar 2026 | 9.8× | 23.92% |
| Dec 2025 | 7.9× | (37.33%) |
| 19 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | 21.2× |
| MBX MBX Biosciences, Inc. compare | 18.1× |
| PHVS Pharvaris N.V. compare | 11.9× |
| CLDX Celldex Therapeutics, Inc. compare | 11.8× |
| NAMS NewAmsterdam Pharma Company N.V. | 11.8× |
| XNCR Xencor, Inc. compare | 6.4× |
| ADMA ADMA Biologics Inc compare | 6.0× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 5.0× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 2.0× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement